#HRMY↓

HRMY/ 02/20/2026 · 4:55 PM

Harmony Biosciences Faces Patent Setback: Analyst Downgrades Stock

Truist analyst downgrades Harmony Biosciences to Hold after unfavorable trial signals on WAKIX patent challenge, warning of early generic entry risk and major franchise threat.

HRMY/ 09/24/2025 · 9:24 AM

Harmony Biosciences Drug Fails Fragile X Trial: What Went Wrong?

Harmony Biosciences’ experimental drug ZYN002 failed its Phase 3 trial for Fragile X syndrome, failing to meet its main goal for improving social avoidance primarily due to a high placebo response.